Hutchmed Reports Lung Data
I denne episoden
- Hutchmed Reports Lung Data
- Dren Bio Secures New Funding
- Bristol Myers Cuts Programs
- BioSpace Examines Australia
- Ono Stops Failed Studies
Kilder
- Pharmatimes: Hutchmed reports phase 3 SANOVO data for first‑line lung cancer
- BioSpace: Dren Bio lands $350M to push rare blood cancer therapy toward market
- BioSpace: Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Its Broader Pipeline - BioSpace
- BioSpace: BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
- BioSpace: Stability, speed and strategy: Inside Australia’s early‑stage edge
- BioSpace: Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.